Simon Hsu, Chief Technology Officer
Professional Overview
Simon Hsu is an accomplished biopharmaceutical executive with over 20 years of experience in technical operations, process development, and contract manufacturing. He currently serves as the Chief Technology Officer at Henlius, a leading global biopharmaceutical company, where he is responsible for driving the company's technical strategy, operations, and external manufacturing collaborations.
Experience Summary
Current Role
As the Chief Technology Officer at Henlius, Simon is responsible for overseeing the company's technical operations, including process development, analytical development, and external manufacturing. He plays a pivotal role in ensuring the successful development and commercialization of Henlius' innovative biologics pipeline, with a focus on improving operational efficiencies and ensuring product quality and supply.
Career Progression
Prior to his current role, Simon held various leadership positions in the biopharmaceutical industry, including Chief Technology Officer at GenSci and HuiGene Therapeutics, as well as senior roles at Pieris Pharmaceuticals, Shire, Bristol-Myers Squibb, MedImmune, and Alexion Pharmaceuticals. Throughout his career, he has demonstrated a track record of driving operational excellence, implementing strategic initiatives, and leading cross-functional teams to deliver complex projects on time and within budget.
Academic Background
Simon holds a Ph.D. in Biochemistry from the University of Massachusetts Amherst, where he specialized in protein engineering and process development. He also earned a Bachelor of Science degree in Chemistry from the National Taiwan University.
Areas of Expertise
- Biologics process development and technical operations
- Analytical method development and validation
- Contract manufacturing and supply chain management
- Regulatory compliance and quality assurance
- Strategic planning and operational optimization
- Cross-functional team leadership and collaboration
Professional Impact
During his tenure at Henlius, Simon has played a pivotal role in the successful development and commercialization of several novel biologic products, including the company's flagship biosimilar candidate. He has also spearheaded initiatives to enhance operational efficiency, improve product quality, and strengthen the company's external manufacturing partnerships.
Conclusion
With his extensive industry experience, technical expertise, and proven leadership abilities, Simon Hsu is well-positioned to continue driving innovation and operational excellence as the Chief Technology Officer at Henlius. His commitment to delivering high-quality biopharmaceutical products and his ability to navigate the complex regulatory landscape make him a valuable asset to the company and the broader biopharmaceutical industry.
